Kylie Sproston is CEO of Bellberry, a not for profit organisation providing streamlined scientific and ethical review of Human Research projects across Australia. A Chartered Engineer, Kylie has expertise across the full pharmaceutical product lifecycle, and has held key positions in both technical and management disciplines in the global Pharmaceutical and Biotech industries. Kylie previously led and managed the Australasian operations of the global group BTG PLC (a specialist healthcare company based in London, UK), as General Manager and Company Director.